Abstract:Praziquantel (PZQ) is the treatment of choice for schistosomiasis, which affects more than 250 million people globally. Commercial tablets contain the crystalline racemic compound (RS-PZQ) which limits drug dissolution and oral bioavailability and can lead to unwanted side effects and poor patient compliance due to the presence of the S-enantiomer. While many approaches have been explored for improving PZQ's dissolution and oral bioavailability, studies focusing on investigating its release from amorphous solid dispersions (ASDs) have been limited. In this work, nucleation induction time experiments were performed to identify suitable polymers for preparing ASDs using RS-PZQ and R-PZQ, the therapeutically active enantiomer. Cellulose-based polymers, hydroxypropyl methylcellulose acetate succinate (HPMCAS, MF grade) and hydroxypropyl methylcellulose (HPMC, E5 LV grade), were the best crystallization inhibitors for RS-PZQ in aqueous media and were selected for ASD preparation using solvent evaporation (SE) and hot-melt extrusion (HME). ASDs prepared experimentally were subjected to X-ray powder diffraction to verify their amorphous nature and a selected number of ASDs were monitored and found to remain physically stable following several months of storage under accelerated-stability testing conditions. SE HPMCAS-MF ASDs of RS-PZQ and R-PZQ showed faster release than HPMC E5 LV ASDs and maintained good performance with an increase in drug loading (DL). HME ASDs of RS-PZQ formulated using HPMCAS-MF exhibited slightly enhanced release compared to that of SE ASDs. SE HPMCAS-MF ASDs showed a maximum release increase of the order of 6 times compared to generic and branded (Biltricide) PZQ tablets. More importantly, SE R-PZQ ASDs with HPMCAS-MF released the drug as effectively as RS-PZQ or better, depending on the DL used. These findings have significant implications for the development of commercial PZQ formulations comprised solely of the R-enantiomer, which can result in mitigation of the biopharmaceutical and compliance issues associated with current commercial tablets.

Preparation and characteristic evaluation of praziquantel solid dispersions in a joint carrier

Dissolution and Oral Bioavailability Enhancement of Praziquantel by Solid Dispersions

Preparation and Physicochemical Characterization of Solid Dispersion of Quercetin and Polyvinylpyrrolidone

Preparation, Characterization and in Vitro Evaluation of Solid Dispersions Containing Docetaxel

Amorphous Solid Dispersion Formation for Enhanced Release Performance of Racemic and Enantiopure Praziquantel

Study of oxaprozin solid dispersions

Studies on Preparation and in Vitro and in Vivo Evaluation of Docetaxel Solid Dispersion

Preparation and Physicochemical Properties of Solid Lipid Nanoparticles Containing Praziquantel

Preparation of Itraconazole Amorphous Solid Dispersion and Preliminary Evaluation in Vitro

Preparation and In Vitro/In Vivo Evaluation of Orally Disintegrating/Modified-Release Praziquantel Tablets

Preparation and in vitro evaluation of curcumin solid dispersions

A Comparison on Preparation Methods for Solid Dispersion of Puerarin

Preparation of Itraconazole Solid Dispersion with PVP and Dissolution Experiment in Vitro

Preparation and Characterization of Solid Dispersion of Carvedilol with PVPVA64

Physical Characterization of Lansoprazole/Pvp Solid Dispersion Prepared by Fluid-Bed Coating Technique

Preparation, Characterization, and Dissolution Studies of Ibuprofen Solid Dispersions Using Polyethylene Glycol (PEG), Talc, and PEG-Talc As Dispersion Carriers

Preparation and in Vitro Study of Solid Dispersions of Cyclosporine A

Preparation and Content Determination of Praziquantel Aquogel Suppository

Study on the Preparation and Dissolution of Flupirtine Maleate Solid Dispersions

Effect of poloxamer solid dispersion on the dissolution of simvastatin

Preparation and Characterization of the Solid Dispersion Quercetin with Phospholipid